Double-Blind, Placebo-Controlled Pilot Randomized Trial of Methylprednisolone Infusion in Pediatric Acute Respiratory Distress Syndrome

Pediatric Critical Care Medicine

Volumn 16, Issue 3, 2015, Pages e74-e81

  Drago, Bonny B ^a   Kimura, Dai ^b   Rovnaghi, Cynthia R ^b   Schwingshackl, Andreas ^b   Rayburn, Mark ^c   Meduri, G Umberto ^d   Anand, Kanwaljeet J S ^b  

^a Prohealth Pediatrics   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

acute respiratory distress syndrome; child; inflammation; lung; mechanical ventilation; steroid

Indexed keywords

METHYLPREDNISOLONE; PLACEBO; GLUCOCORTICOID; OXYGEN;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CHILDHOOD MORTALITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SURVEILLANCE PROGRAM; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LOW DRUG DOSE; LUNG COMPLIANCE; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; BLOOD; BLOOD GAS ANALYSIS; CHILD; FEMALE; INFANT; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ADMINISTRATION; LENGTH OF STAY; MALE; MORTALITY; NEWBORN; PATHOPHYSIOLOGY; PILOT STUDY; PRESCHOOL CHILD; RESPIRATORY DISTRESS SYNDROME, ADULT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

BLOOD GAS ANALYSIS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; GLUCOCORTICOIDS; HOSPITAL MORTALITY; HUMANS; INFANT; INFANT, NEWBORN; INFUSIONS, INTRAVENOUS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; METHYLPREDNISOLONE; OXYGEN; PILOT PROJECTS; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; TREATMENT OUTCOME;

EID: 84937642613     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/PCC.0000000000000349     Document Type: Article

References (56)

1. Khemani RG, Smith LS, Zimmerman JJ, et al: Pediatric acute respiratory distress syndrome (ARDS): Definition, incidence and epidemiology. Pediatr Crit Care Med 2014; In Press
2. Flori HR, Glidden DV, Rutherford GW, et al: Pediatric acute lung injury: Prospective evaluation of risk factors associated with mortality. Am J Respir Crit Care Med 2005; 171:995-1001
3. López-Fernández Y, Azagra AM, de la Oliva P, et al; Pediatric Acute Lung Injury Epidemiology and Natural History (PED-ALIEN) Network: Pediatric acute lung injury epidemiology and natural history study: Incidence and outcome of the acute respiratory distress syndrome in children. Crit Care Med 2012; 40:3238-3245
4. Zimmerman JJ, Akhtar SR, Caldwell E, et al: Incidence and outcomes of pediatric acute lung injury. Pediatrics 2009; 124:87-95
5. Rubenfeld GD, Caldwell E, Peabody E, et al: Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353:1685-1693
6. Cely CM, Rojas JT, Maldonado DA, et al: Use of intensive care, mechanical ventilation, both, or neither by patients with acute lung injury. Crit Care Med 2010; 38:1126-1134
7. Stapleton RD, Wang BM, Hudson LD, et al: Causes and timing of death in patients with ARDS. Chest 2005; 128:525-532
8. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000; 342:1301-1308
9. Relvas MS, Silver PC, Sagy M: Prone positioning of pediatric patients with ARDS results in improvement in oxygenation if maintained > 12 h daily. Chest 2003; 124:269-274
10. Curley MA, Hibberd PL, Fineman LD, et al: Effect of prone positioning on clinical outcomes in children with acute lung injury: A randomized controlled trial. JAMA 2005; 294:229-237
11. Kopterides P, Siempos II, Armaganidis A: Prone positioning in hypoxemic respiratory failure: Meta-analysis of randomized controlled trials. J Crit Care 2009; 24:89-100
12. Wiedemann HP, Wheeler AP, Bernard GR, et al: Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006; 354:2564-2575
13. Thiel M, Chouker A, Ohta A, et al: Oxygenation inhibits the physiological tissue-protecting mechanism and thereby exacerbates acute inflammatory lung injury. PLoS Biol 2005; 3:e174
14. Jackson RM: Molecular, pharmacologic, and clinical aspects of oxygen-induced lung injury. Clin Chest Med 1990; 11:73-86
15. Martin DS, Grocott MP: Oxygen therapy in critical illness: Precise control of arterial oxygenation and permissive hypoxemia. Crit Care Med 2013; 41:423-432
16. Yapicioʇlu H, Yildizdaş D, Bayram I, et al: The use of surfactant in children with acute respiratory distress syndrome: Efficacy in terms of oxygenation, ventilation and mortality. Pulm Pharmacol Ther 2003; 16:327-333
17. Willson DF, Thomas NJ: Surfactant composition and biophysical properties are important in clinical studies. Am J Respir Crit Care Med 2010; 181:762; author reply 763
18. Willson DF, Thomas NJ, Markovitz BP, et al; Pediatric Acute Lung Injury and Sepsis Investigators: Effect of exogenous surfactant (calfactant) in pediatric acute lung injury: A randomized controlled trial. JAMA 2005; 293:470-476
19. Willson DF, Thomas NJ, Tamburro R, et al; Pediatric Acute Lung and Sepsis Investigators Network: Pediatric calfactant in acute respiratory distress syndrome trial. Pediatr Crit Care Med 2013; 14:657-665
20. Papazian L, Forel JM, Gacouin A, et al; ACURASYS Study Investigators: Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010; 363:1107-1116
21. Alhazzani W, Alshahrani M, Jaeschke R, et al: Neuromuscular blocking agents in acute respiratory distress syndrome: A systematic review and meta-analysis of randomized controlled trials. Crit Care 2013; 17:R43
22. Hall JB: Point: Should paralytic agents be routinely used in severe ARDS? Yes. Chest 2013; 144:1440-1442
23. Sessler CN: Counterpoint: Should paralytic agents be routinely used in severe ARDS? No. Chest 2013; 144:1442-1445
24. Randolph AG: Management of acute lung injury and acute respiratory distress syndrome in children. Crit Care Med 2009; 37:2448-2454
25. Afshari A, Brok J, Moller AM, et al: Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010; 7:CD002787
26. Adhikari NK, Burns KE, Friedrich JO, et al: Effect of nitric oxide on oxygenation and mortality in acute lung injury: Systematic review and meta-analysis. BMJ 2007; 334:779
27. Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007; 131:954-963
28. Meduri GU, Marik PE, Chrousos GP, et al: Steroid treatment in ARDS: A critical appraisal of the ARDS network trial and the recent literature. Intensive Care Med 2008; 34:61-69
29. Tang BM, Craig JC, Eslick GD, et al: Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. Crit Care Med 2009; 37:1594-1603
30. Meduri GU, Annane D, Chrousos GP, et al: Activation and regulation of systemic inflammation in ARDS: Rationale for prolonged glucocorticoid therapy. Chest 2009; 136:1631-1643
31. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349
32. Meduri GU, Muthiah MP, Carratu P, et al: Nuclear factor-kappaB- and glucocorticoid receptor alpha-mediated mechanisms in the regulation of systemic and pulmonary inflammation during sepsis and acute respiratory distress syndrome. Evidence for inflammation-induced target tissue resistance to glucocorticoids. Neuroimmunomodulation 2005; 12:321-338
33. Confalonieri M, Urbino R, Potena A, et al: Hydrocortisone infusion for severe community-acquired pneumonia: A preliminary randomized study. Am J Respir Crit Care Med 2005; 171:242-248
34. Sabry NA, Omar EE-D: Corticosteroids and ICU course of community acquired pneumonia in Egyptian settings. Pharmacol Pharm 2011; 2:73-81
35. Annane DS, Sébille V, Bellissant E, for the Ger-Inf-05 Study Group: Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34:22-30
36. Meduri GU, Golden E, Freire AX, et al: Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007; 131:954-963
37. Rezk N, Ibrahim A: Effects of methylprednisolone in early ARDS. Egypt J Chest Dis Tuberc 2013; 62:167-172
38. Meduri GU, Headley AS, Golden E, et al: Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 1998; 280:159-165
39. Steinberg KP, Hudson LD, Goodman RB, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network: Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006; 354:1671-1684
40. Martinot A, Fourier C, Cremer R, et al: Short-course, high-dose corticosteroid treatment in six children with late ARDS. Pediatr Pulmonol 1997; 23:314-316
41. Goh AY, Sekaran D, Roziah M: Corticosteroid rescue in late paediatric acute respiratory distress syndrome. Respirology 1999; 4:295-297
42. Guglani L, Jain S, Lodha R: Methylprednisolone therapy in a child with unresolving ARDS. Indian Pediatr 2006; 43:639-642
43. De Luca D, Minucci A, Cogo P, et al: Secretory phospholipase A2 pathway during pediatric acute respiratory distress syndrome: A preliminary study. Pediatr Crit Care Med 2011; 12:e20-e24
44. Marshall RP, Webb S, Bellingan GJ, et al: Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. Am J Respir Crit Care Med 2002; 166:646-650
45. Plunkett A, Agbeko RS, Li K, et al: Angiotensin-converting enzyme D allele does not influence susceptibility to acute hypoxic respiratory failure in children. Intensive Care Med 2008; 34:2279-2283
46. Honiden S, Gong MN: Diabetes, insulin, and development of acute lung injury. Crit Care Med 2009; 37:2455-2464
47. Burri PH: Structural aspects of postnatal lung development-Alveolar formation and growth. Biol Neonate 2006; 89:313-322
48. Smith LS, Zimmerman JJ, Martin TR: Mechanisms of acute respiratory distress syndrome in children and adults: A review and suggestions for future research. Pediatr Crit Care Med 2013; 14:631-643
49. Bernard GR, Artigas A, Brigham KL, et al: Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med 1994; 20:225-232
50. Altman DG, Schulz KF, Moher D, et al; CONSORT GROUP (Consolidated Standards of Reporting Trials): The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001; 134:663-694
51. Raurich JM, Ferreruela M, Llompart-Pou JA, et al: Potential effects of corticosteroids on physiological dead-space fraction in acute respiratory distress syndrome. Respir Care 2012; 57:377-383
52. Tang B, Craig JC, Eslick GD, et al: Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: A systematic review and meta-analysis. Crit Care Med 2009; 37:1594-1603
53. Slutsky AS, Ranieri VM: Ventilator-induced lung injury. N Engl J Med 2013; 369:2126-2136
54. Bernard GR, Luce JM, Sprung CL, et al: High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317:1565-1570
55. Khemani RG, Newth CJ: The design of future pediatric mechanical ventilation trials for acute lung injury. Am J Respir Crit Care Med 2010; 182:1465-1474
56. Khemani RG, Wilson DF, Esteban A, et al: Evaluating the Berlin Definition in pediatric ARDS. Intensive Care Med 2013; 39:2213-2216